• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
Contact
  • Home
  • News
  • News
  • Electronic submission for China drug registration applications

Electronic submission for China drug registration applications

Electronic submission for China drug registration
Thursday, 29 December 2022 / Published in News, NMPA Registration in China, Pharmaceuticals & DMF

Electronic submission for China drug registration applications

Electronic submission for China drug registration applications will be available from January 1, 2023, onwards.

The National Medical Products Administration (NMPA) announced the implementation of electronic submission format for drug registration applications on November 30, 2022, whilst the Center for Drug Evaluation (CDE) issued a notice to address the requirements for electronic application for drug registrations on December 2, 2022.

Highlights

  • Electronic submission of drug registration applications will be accepted by the Chinese regulator from January 1, 2023, onwards, by meeting the requirements of:
    • Template format
    • Document format
    • Document name
    • File size
    • Page numbering
    • File compression / encryption
    • Electronic signature
    • Disc format
  • Applicants no longer need to submit the application dossiers in paper format.
  • The new submission format of drug registration applications does not affect the existing working procedures.

Background information

Paper submission used to be the main method for drug registration in China. The CDE website first launched the electronic data submission column for applicants in 2012, and made improvements over the years by introducing the online drug master filing platform for active pharmaceutical ingredients (APIs), excipients and packaging materials where application dossiers were accepted in electronic format via CD-ROMs.

The online website was upgraded in 2019 to include a new function for filling in and submitting the application form online, however, the application dossiers for drug registrations were still only accepted in paper form.

On September 30, 2021, NMPA issued an announcement, requiring that from December 29, 2021, onwards, the application for marketing license of chemical drug registration category 1 and 5.1, as well as biological products for treatment and biological products for prevention can be filed according to eCTD. Other types of drugs and classifications for registration should still be implemented according to the previous requirements.

Due to the need for pandemic prevention and control, the CDE issued a new requirement for drug registration applicants in January 2022 to submit the application dossiers via electronic CD-ROMs first, and submit the hard copy version after the official review approval. Electronic payment for registration fees were also accepted.

Recently, the NMPA announced the issuance of electronic certificates for eligible drug registrations in China from November 1, 2022, onwards.

Further information

Click here to read the NMPA announcement in full.

Click here to read the CDE announcement on submission requirements.

If you would like to know more about the electronic submission requirements, or if you need our support with the registration of your drug product in China, please contact us.

GET IN TOUCH

🌐 Send us your enquiry
📚 Request our whitepapers
📣 Sign up for our newsletter

What you can read next

2021 China Medical Device Standards Catalogue Released
Cisema experts cited in drug-device combination news
NMPA Major Updates Concerning Software as Medical Device (SaMD)

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • China cosmetics efficacy claims FAQ

    China cosmetics efficacy claims FAQ available to answer key questions

    China cosmetics efficacy claims FAQ is availabl...
  • China cosmetics GMP inspections

    China cosmetics GMP inspections points have been finalised

    China cosmetics GMP inspections points and judg...
  • China medical device quality safety responsibility

    China medical device quality and safety responsibility regulations come into force on March 1, 2023

    China medical device quality and safety respons...
  • China drug standards draft measures

    China drug standards draft measures have been published by the NMPA

    China drug standards draft measures have recent...
  • China special equipment safety supervision

    China special equipment safety supervision – draft provisions released

    China special equipment safety supervision regu...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP
Cookies on Cisema
Learn more about Cisema's Privacy Policy.